IL2 and familial pancreatic carcinoma: TPV/eGFP was used as a “wt” control virus and TPV/∆66R/m-CCL-2/mCherry and TPV/∆66R/m-IL-2/mCherry were selected specifically to assess mCCL-2 and mIL-2 immunomodulatory activity in combination with TPV oncolytic activity against pancreatic cancer due to the known biological activity of mCCL-2 and mIL-2 [84,85,86,87,88,89,90,91,92,93].